A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Exclusion Criteria

• •Significant neurological disorder or history of seizure
• •Know clinically significant cardiac rhythm or cardiac disorder
• •History of sudden infant death in a sibling
• •Clinically significant chromosome abnormality
• •History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
• •Diseases that could cause pruritic and/or sleep disruption
• •Immunocompromised
• •Current chronic or acute infection requiring treatment
• •Use of prohibited medication(s) or procedure(s)
• •Use of prohibited medications by breastfeeding mother if breastfeeding participant